If You Invested in Cybin Inc (HELP)

Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company developing proprietary neuroactive compounds for mental health conditions. The company describes these compounds as novel serotonergic agonists, or NSAs: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. Its listed securities trade under the symbol HELP on Nasdaq and Cboe Canada.

The company's development work is centered on depression, anxiety, and other mental health conditions. Its lead disclosed program, HLP003, is a proprietary NSA in clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004 is a proprietary NSA in clinical development for generalized anxiety disorder. Helus Pharma also reports a broader research portfolio of investigational NSAs.

Helus Pharma's business model is organized around pharmaceutical research and clinical development rather than commercial product sales. Its operating activities include advancing investigational compounds through clinical programs, engaging with regulators, building medical and scientific capabilities, and supporting clinical research participation for its mental health pipeline. The company has described operations in Canada, the United States, the United Kingdom, and Ireland.

As a public clinical-stage issuer, Helus Pharma's corporate record includes pipeline updates, clinical and regulatory disclosures, governance changes, capital-structure matters, and operating and financial results. The company was formerly known to public markets as Cybin Inc. while using Helus Pharma as its commercial operating name.